They could be the ones shorting the stock...Add Johnson & Johnson to that list. Once there was a serious researcher (Witkowski) put in charge, the real threat materialized. Turf protection became more important than c-peptide protection. As for Medtronic, they must wonder how they can monetize the platform across indications other than as an artificial pancreas. Owning a F350 Lariet is great for utility, but is kind of out of place in an F1 competition. Different specificities may not be what a Medtronic is after. But all the large pharmaceuticals know that if islets survive without immunosuppressant, the game changes forever. Now, can Frank and Phillip monetize THAT.